Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2020-02-26
DOI
10.1080/14740338.2020.1734560
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adalimumab Medium‐Term Dosing Strategy in Moderate‐to‐Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo‐Controlled, PIONEER Trials
- (2019) G.B.E. Jemec et al. BRITISH JOURNAL OF DERMATOLOGY
- Associations of cutaneous and extra‐cutaneous infections with Hidradenitis Suppurativa in US children and adults
- (2019) H. H. Lee et al. BRITISH JOURNAL OF DERMATOLOGY
- Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective
- (2019) Youwei Bi et al. AAPS Journal
- Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
- (2019) Akimichi Morita et al. JOURNAL OF DERMATOLOGY
- Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
- (2019) Gerd R. Burmester et al. ADVANCES IN THERAPY
- Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab
- (2019) R.D. Caposiena Caro et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials
- (2019) H.H. Zee et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
- (2018) Caitriona Ryan et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas
- (2018) Cathy Yunjia Zhao et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child
- (2018) P. Sahu et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa
- (2018) D. Jiménez-Gallo et al. CYTOKINE
- Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
- (2018) Christos C. Zouboulis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States
- (2018) Amit Garg et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Should we provide anti-HPV vaccination for patients with genital hidradenitis suppurativa?
- (2018) A Nikkels et al. BRITISH JOURNAL OF DERMATOLOGY
- Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
- (2018) Miriam Calao et al. PLoS One
- Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient
- (2018) Alejandro Molina-Leyva et al. AIDS
- Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
- (2017) Marta Pérez-De-Lis et al. Expert Opinion On Drug Safety
- Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
- (2017) Toshinobu Matsui et al. International Journal of Medical Sciences
- Hidradenitis Suppurativa
- (2017) Ditte Marie Lindhardt Saunte et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study
- (2017) Ariela Hoxha et al. JOINT BONE SPINE
- Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience
- (2017) Gabrielle Brown et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study
- (2017) Inge E. Deckers et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis
- (2017) Amit Garg et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature
- (2017) S. Piaserico et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zheng Zhang et al. BMJ Open
- Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States
- (2017) Amit Garg et al. JAMA Dermatology
- Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy
- (2017) Ana Esteve-Solé et al. Frontiers in Immunology
- Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS
- (2016) Stephanie M. Gallitano et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
- (2016) Alexa B. Kimball et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease
- (2015) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study
- (2015) Corinna Weber-Schoendorfer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013
- (2015) E. Sbidian et al. BRITISH JOURNAL OF DERMATOLOGY
- Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center
- (2015) Mital Patel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Compartmentalized Cytokine Responses in Hidradenitis Suppurativa
- (2015) Theodora Kanni et al. PLoS One
- The Use of Biologic Agents in Pregnancy and Breastfeeding
- (2014) Sara Horst et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Use of biological treatments in patients with hidradenitis suppurativa
- (2014) G. Martin-Ezquerra et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options
- (2014) Peter Riis Mikkelsen et al. PEDIATRIC DRUGS
- Association of Metabolic Syndrome and Hidradenitis Suppurativa
- (2014) Iben Marie Miller et al. JAMA Dermatology
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- (2013) Alexa B. Kimball et al. ANNALS OF INTERNAL MEDICINE
- The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa
- (2013) G.R. Vinding et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study
- (2012) Maria Esposito et al. DERMATOLOGY
- Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency
- (2012) Keiichi Sumida et al. ARTHRITIS CARE & RESEARCH
- Severe Hidradenitis Suppurative in an HIV-Positive Male: Use of Multiple Treatment Modalities, Including Tumor Necrosis Factor Blockade
- (2011) Husein Husein-ElAhmed et al. AIDS PATIENT CARE AND STDS
- Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab
- (2011) Ilaria Puxeddu et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
- (2011) I. Miller et al. BRITISH JOURNAL OF DERMATOLOGY
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa
- (2011) Dominique C. van Rappard et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Severe Refractory Hidradenitis Suppurativa in an HIV-Positive Patient Successfully Treated With Infliximab
- (2010) Diana Alecsandru et al. ARCHIVES OF DERMATOLOGY
- A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa
- (2010) Masahiro Amano et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy
- (2010) Monika Arenbergerova et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
- (2010) Annika Grant et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?
- (2009) L Matusiak et al. ACTA DERMATO-VENEREOLOGICA
- Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa
- (2009) Ricardo Blanco et al. ARCHIVES OF DERMATOLOGY
- Adalimumab Level in Breast Milk of a Nursing Mother
- (2009) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Clinicopathological Study of 13 Cases of Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa
- (2009) C. Lavogiez et al. DERMATOLOGY
- What causes hidradenitis suppurativa?
- (2009) Lübeck Ralf Paus et al. EXPERIMENTAL DERMATOLOGY
- Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies
- (2008) Jean E. Revuz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started